BioAtla, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCAB$1.74-44.7%Stored close · as of Aug 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common stock · Class Bcommon stock · Additionalpaid-in · Accumulated · Totalstockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | equity (deficit) | |
| Balance at December 31, 2023 | 48,077,599 | $5 | — | $— | $486,930 | $(416,263) | $70,672 |
| Issuance of common stock, net of issuance costs and warrant liability | 9,679,158 | 1 | — | — | 4,151 | — | 4,152 |
| Issuance of common stock under equity incentive plans, net of shares withheld for taxes | 76,995 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 265,412 | — | — | — | 342 | — | 342 |
| Taxes related to net share settlement of equity awards | — | — | — | — | (46) | — | (46) |
| Stock-based compensation expense | — | — | — | — | 8,921 | — | 8,921 |
| Net loss | — | — | — | — | — | (69,776) | (69,776) |
| Balance at December 31, 2024 | 58,099,164 | $6 | — | $— | $500,298 | $(486,039) | $14,265 |
| Issuance of common stock under equity incentive plans, net of shares withheld for taxes | 627,739 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 256,831 | — | — | — | 100 | — | 100 |
| Issuance of common stock for commitment fee under SEPA | 243,428 | — | — | — | 282 | — | 282 |
| Issuance of common stock under PPAs | 4,237,160 | — | — | — | 3,389 | — | 3,389 |
| Taxes related to net share settlement of equity awards | — | — | — | — | (52) | — | (52) |
| Stock-based compensation expense | — | — | — | — | 5,434 | — | 5,434 |
| Net loss | — | — | — | — | — | (59,607) | (59,607) |
| Balance at December 31, 2025 | 63,464,322 | $6 | — | $— | $509,451 | $(545,646) | $(36,189) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.